SLC5A2 and atrial fibrillation: In the retrospective trial conducted by Suzuki et al. [45], the incidence of subsequent cardiovascular risk in terms of HF, myocardial infarction, angina, stroke, and atrial fibrillation was compared in accordance with individual SGLT-2 inhibitors.